knowledge -WSS

knowledge

author：leisure time 2025-09-30 20:34:45 - browse：516

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

focus

WSS

CDC advisory group OKs chikungunya vaccine

Cholera vaccine supplies dangerously low, outbreaks surging

Childhood vaccination ad campaign launches in the U.K.

Israel withdraws forces after 2

Virtual repurposing can help discover new uses for existing drugs

Ohio train derailment: Experts on toxic chemical risks

entertainment

knowledge

knowledge

Heart attack and stroke risk calculators need revising

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

23andMe had bad news about my health. I wish a person had delivered it

EU moves toward latest gene techniques in food production to counter climate change, shortages

The high cost of giving birth even with insurance

Study fuels hope CAR

After affirmative action ruling, medical educators look to 'holistic review'

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

Cancer drug shortages should be causing more outrage

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

leisure time

Study fuels hope CAR

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

EU moves toward latest gene techniques in food production to counter climate change, shortages

Children’s Hospital revives plan for pedestrian bridge

2 million sign

Adele warns fans about throwing things at performers onstage

entertainment

entertainment

focus

knowledge